Univercells receives grant to develop antibody production platform

Univercells, a company dedicated to delivering biomanufacturing solutions, has received a grant from the Walloon Region in Belgium that will be used to develop an antibody production platform.

The funding, worth €2.4 million, will enable the company to launch a programme aimed at developing its innovative protein platform, thereby leading to a cost-effective way of producing biosimilars.

“We are very appreciative of the continuing insight and support from Wallonia,” stated Hugues Bultot, co-founder and CEO of Univercells. “The region has supported Univercells since its early days, with a successful earlier project leading to the commercial development of our vaccine micro-facility. We are confident this second platform will demonstrate the same favourable outcome and aid in fostering access to healthcare worldwide.”

Last year, the company successfully closed a €3 million capital increase in a Series-A equity financing round, led by private investors. Prior to that the company received a $12 million grant from the Bill & Melinda Gates Foundation and €3 million from Takeda in 2015